SEC Form 10-Q filed by Xenon Pharmaceuticals Inc.
$XENE
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | $50.00 | Outperform | Raymond James |
| 10/1/2024 | $53.00 | Buy | H.C. Wainwright |
| 1/4/2024 | $62.00 | Buy | Citigroup |
| 12/8/2023 | $63.00 | Outperform | Robert W. Baird |
| 10/24/2023 | Overweight | Cantor Fitzgerald | |
| 4/25/2023 | $58.00 | Overweight | Cantor Fitzgerald |
| 12/14/2022 | $60.00 | Buy | Goldman |
| 12/12/2022 | Outperform | Cowen |
RBC Capital analyst Brian Abrahams reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and maintains $55 price target.
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and maintains $62 price target.
Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS and findings around mental health and comorbidity burdens of FOSNew pre-clinical data from the Company's Nav1.1 program VANCOUVER, British Columbia and BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (AES 2024), taking place December 6-10, 2024 at the Los Angeles Convention Center in Los An
VANCOUVER, British Columbia and BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences. Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 9:10 a.m. ET (webcast link)Jefferies London Healthcare Conference 2024 on Wednesday, November 20, 2024 at 1:30 PM GMT / 8:30 am ET (webcast link) Details about company presentations, webcasts, and other events can be found on the "Investors" section of Xenon's website. When avai
– Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES – Phase 3 MDD program on track with X-NOVA2 study expected to initiate by year-end – Expanding ion channel portfolio includes multiple candidates advancing towards IND filings in 2025 – Recent appointment of Matt Ronsheim, experienced pharmaceutical executive joining Xenon's senior executive team as Chief Operating Officer – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focuse
Raymond James resumed coverage of Xenon Pharmaceuticals with a rating of Outperform and set a new price target of $50.00
H.C. Wainwright initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $53.00
Citigroup initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $62.00
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
144 - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
10-Q - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
– Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES – Phase 3 MDD program on track with X-NOVA2 study expected to initiate by year-end – Expanding ion channel portfolio includes multiple candidates advancing towards IND filings in 2025 – Recent appointment of Matt Ronsheim, experienced pharmaceutical executive joining Xenon's senior executive team as Chief Operating Officer – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focuse
VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its third quarter 2024 financial results after the close of U.S. financial markets on Tuesday, November 12, 2024. Conference Call/Webcast Information: Date: Tuesday, November 12, 2024 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID:7128308 A live webcast of the com
— Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025— MDD program on track with Phase 3 study expected to initiate in H2 2024— Multiple Kv7 and Nav1.7 candidates progressing towards development with INDs expected in 2025— Conference call at 4:30 pm ET today VANCOUVER, British Columbia, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. "We are proud to have the only Kv7
VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the Xenon senior executive team. In this new role, Dr. Ronsheim will lead Chemistry, Manufacturing and Controls (CMC), Program Management and Quality Assurance and as a member of the senior executive team will be responsible for providing strategic and operational leadership for the Company's pipeline of small molecule progr
BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. Ms. DiFabio will provide strategic leadership and oversight of the planning and execution for Xenon's legal function on a global basis. Mr. Ian Mortimer, Xenon's President and Chief Executive Officer, stated, "We are very pleased to welcome Andrea to Xenon's senior leadership team in the newly created role of Chief Legal Officer. Andrea joins us at a time when we have multiple late-stage clinical programs underway with the
BURNABY, British Columbia, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Christopher Kenney, M.D. as Chief Medical Officer, effective immediately. Dr. Kenney will oversee all clinical development and medical affairs strategies, guiding the development of Xenon's portfolio of neurology-focused therapeutic programs. Mr. Ian Mortimer, Xenon's President and Chief Executive Officer, stated, "We are thrilled to welcome Chris to the Xenon senior leadership team as we enter an important period with multiple mid- to late-stage programs advancing within our neurology pipeline and continue